0940 GMT - Novartis's positive late-stage results for its blood-disorder treatment Fabhalta speak for the efficacy of the drug in treating other diseases, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's drug, already approved for chronic kidney disorder, is currently being tested in two rare kidney diseases. "Novartis sees peak sales for the drug of $3+ billion--which we roughly match in our modeling--but still risk adjust our revenue estimates by 40% in indications, where we have not yet seen clinical data," the analyst says. Shares fall 0.2% to 90.23 Swiss francs. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
December 06, 2024 04:43 ET (09:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.